L
Lidia Oostvogels
Researcher at GlaxoSmithKline
Publications - 59
Citations - 2738
Lidia Oostvogels is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Zoster vaccine & Reactogenicity. The author has an hindex of 20, co-authored 55 publications receiving 1915 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Anthony L. Cunningham,Himal Lal,Martina Kovac,Roman Chlibek,Shinn-Jang Hwang,Javier Díez-Domingo,Olivier Godeaux,Myron J. Levin,Janet E. McElhaney,Joan Puig-Barberà,C. Vanden Abeele,Timo Vesikari,Daisuke Watanabe,Toufik Zahaf,Anitta Ahonen,Eugene Athan,J. F. Barba-Gomez,Laura Campora,F. de Looze,H. J. Downey,Wayne Ghesquiere,Iris Gorfinkel,Tiina Korhonen,Edward M. F. Leung,Shelly A. McNeil,Lidia Oostvogels,Lars Rombo,Jan Smetana,Lily Yin Weckx,Wilfred W Yeo,Thomas C. Heineman +30 more
TL;DR: HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older.
Journal ArticleDOI
Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness
Ann R. Falsey,Janet E. McElhaney,Jiri Beran,Gerrit A van Essen,Xavier Duval,Meral Esen,Florence Galtier,Pierre Gervais,Shinn-Jang Hwang,Peter G. Kremsner,Odile Launay,Geert Leroux-Roels,Shelly A. McNeil,Andrzej Nowakowski,Jan Hendrik Richardus,Guillermo M. Ruiz-Palacios,Suzanne St Rose,Jeanne-Marie Devaster,Lidia Oostvogels,Serge Durviaux,Sylvia Taylor +20 more
TL;DR: This first global study providing data on RSV disease in ≥65 year-olds confirms that RSV is an important respiratory pathogen in the elderly and preventative measures such as vaccination could decrease severe respiratory illnesses and complications inThe elderly.
Journal ArticleDOI
Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
Elchonon M. Berkowitz,Graeme Moyle,Hans-Jürgen Stellbrink,Dirk Schürmann,Stephen Kegg,Matthias Stoll,Mohamed El Idrissi,Lidia Oostvogels,Thomas C. Heineman,Norbert H. Brockmeyer,Edwin DeJesus,Stefan Esser,Trevor Hawkins,Jacob Lalezari,Chloe Orkin,Stefan Schneider +15 more
TL;DR: HZ/su was immunogenic and had a clinically acceptable safety profile in HIV-infected adults and no sustained impact on HIV load or CD4+ T-cell count was noted following vaccinations.
Journal ArticleDOI
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
Janet E. McElhaney,Jiri Beran,Jeanne-Marie Devaster,Meral Esen,Odile Launay,Geert Leroux-Roels,Guillermo M. Ruiz-Palacios,Gerrit A van Essen,Adrian Caplanusi,Carine Claeys,Christelle Durand,Xavier Duval,Mohamed El Idrissi,Ann R. Falsey,Gregory Feldman,Sharon E. Frey,Florence Galtier,Shinn-Jang Hwang,Shinn-Jang Hwang,Bruce L. Innis,Martina Kovac,Peter G. Kremsner,Shelly A. McNeil,Andrzej Nowakowski,Jan Hendrik Richardus,Andrew F. Trofa,Lidia Oostvogels +26 more
TL;DR: AS03-adjuvanted inactivated trivalent influenza vaccine (TIV) has a higher efficacy for prevention of some subtypes of influenza than does a non-adJuvanted TIV, and future influenza vaccine studies in elderly people should be based on subtype or lineage-specific endpoints.
Journal ArticleDOI
Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.
Kong Boo Phua,Fong Seng Lim,Yu-Lung Lau,Edmund A S Nelson,Li-Min Huang,Seng Hock Quak,Bee Wah Lee,Yee Leong Teoh,Yee Leong Teoh,Haiwen Tang,Irving Boudville,Lidia Oostvogels,P.V. Suryakiran,Igor Smolenov,H.H. Han,H.L. Bock +15 more
TL;DR: RIX4414 shows a good safety profile and offers high protection during the first 2 years of life with potentially significant public health impact in this population of Asian infants from high-income countries.